KPC Pharmaceuticals Inc

SHG:600422 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.25 Billion
CN¥9.20 Billion CNY
Market Cap Rank
#8207 Global
#1510 in China
Share Price
CN¥12.15
Change (1 day)
+0.00%
52-Week Range
CN¥11.87 - CN¥18.36
All Time High
CN¥24.62
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotics,… Read more

KPC Pharmaceuticals Inc (600422) - Net Assets

Latest net assets as of September 2025: CN¥6.86 Billion CNY

Based on the latest financial reports, KPC Pharmaceuticals Inc (600422) has net assets worth CN¥6.86 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥12.01 Billion) and total liabilities (CN¥5.15 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥6.86 Billion
% of Total Assets 57.1%
Annual Growth Rate 15.68%
5-Year Change 46.57%
10-Year Change 102.23%
Growth Volatility 56.64

KPC Pharmaceuticals Inc - Net Assets Trend (1997–2024)

This chart illustrates how KPC Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for KPC Pharmaceuticals Inc (1997–2024)

The table below shows the annual net assets of KPC Pharmaceuticals Inc from 1997 to 2024.

Year Net Assets Change
2024-12-31 CN¥6.75 Billion +23.18%
2023-12-31 CN¥5.48 Billion +6.50%
2022-12-31 CN¥5.14 Billion +4.09%
2021-12-31 CN¥4.94 Billion +7.34%
2020-12-31 CN¥4.60 Billion +6.20%
2019-12-31 CN¥4.33 Billion +9.77%
2018-12-31 CN¥3.95 Billion +4.63%
2017-12-31 CN¥3.77 Billion +4.48%
2016-12-31 CN¥3.61 Billion +8.28%
2015-12-31 CN¥3.34 Billion +62.75%
2014-12-31 CN¥2.05 Billion +9.07%
2013-12-31 CN¥1.88 Billion +77.83%
2012-12-31 CN¥1.06 Billion +15.17%
2011-12-31 CN¥917.52 Million +11.87%
2010-12-31 CN¥820.15 Million +11.08%
2009-12-31 CN¥738.35 Million +10.12%
2008-12-31 CN¥670.50 Million +5.56%
2007-12-31 CN¥635.17 Million +8.79%
2006-12-31 CN¥583.86 Million -0.71%
2005-12-31 CN¥588.02 Million -18.69%
2004-12-31 CN¥723.20 Million +9.58%
2003-12-31 CN¥659.95 Million +15.54%
2002-12-31 CN¥571.17 Million +2.04%
2001-12-31 CN¥559.74 Million +0.38%
2000-12-31 CN¥557.64 Million +295.69%
1999-12-31 CN¥140.93 Million +0.39%
1998-12-31 CN¥140.38 Million +6.27%
1997-12-31 CN¥132.10 Million --

Equity Component Analysis

This analysis shows how different components contribute to KPC Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 361112710865.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥3.60 Billion 68.56%
Common Stock CN¥756.98 Million 14.41%
Other Components CN¥894.91 Million 17.03%
Total Equity CN¥5.25 Billion 100.00%

KPC Pharmaceuticals Inc Competitors by Market Cap

The table below lists competitors of KPC Pharmaceuticals Inc ranked by their market capitalization.

Company Market Cap
Yantai China Pet Foods Co Ltd
SHE:002891
 		$801.80 Million
Global Power Synergy Public Company Limited
BK:GPSC-R
 		$801.90 Million
KRUNGTHAI CARD FGN BA 1
F:KRTA
 		$801.94 Million
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
 		$802.48 Million
SJM Holdings Ltd
PINK:SJMHF
 		$801.54 Million
Alphawave IP Group plc
PINK:AWEVF
 		$801.26 Million
Greattown Holdings Ltd A
SHG:600094
 		$801.09 Million
IRISH CONTINENTAL GRP UTS
F:IR5B
 		$800.71 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in KPC Pharmaceuticals Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 5,297,444,082 to 5,253,648,545, a change of -43,795,537 (-0.8%).
  • Net income of 648,081,345 contributed positively to equity growth.
  • Dividend payments of 172,544,936 reduced retained earnings.
  • Share repurchases of 2,208,928 reduced equity.
  • Other factors decreased equity by 517,123,018.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥648.08 Million +12.34%
Dividends Paid CN¥172.54 Million -3.28%
Share Repurchases CN¥2.21 Million -0.04%
Other Changes CN¥-517.12 Million -9.84%
Total Change CN¥- -0.83%

Book Value vs Market Value Analysis

This analysis compares KPC Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.74x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 88.16x to 1.74x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1997-12-31 CN¥0.14 CN¥12.15 x
1998-12-31 CN¥0.14 CN¥12.15 x
1999-12-31 CN¥0.16 CN¥12.15 x
2000-12-31 CN¥0.81 CN¥12.15 x
2001-12-31 CN¥0.83 CN¥12.15 x
2002-12-31 CN¥0.60 CN¥12.15 x
2003-12-31 CN¥0.68 CN¥12.15 x
2004-12-31 CN¥0.75 CN¥12.15 x
2005-12-31 CN¥0.82 CN¥12.15 x
2006-12-31 CN¥0.83 CN¥12.15 x
2007-12-31 CN¥0.91 CN¥12.15 x
2008-12-31 CN¥0.97 CN¥12.15 x
2009-12-31 CN¥1.06 CN¥12.15 x
2010-12-31 CN¥1.17 CN¥12.15 x
2011-12-31 CN¥1.30 CN¥12.15 x
2012-12-31 CN¥1.49 CN¥12.15 x
2013-12-31 CN¥2.70 CN¥12.15 x
2014-12-31 CN¥2.44 CN¥12.15 x
2015-12-31 CN¥4.20 CN¥12.15 x
2016-12-31 CN¥4.51 CN¥12.15 x
2017-12-31 CN¥4.67 CN¥12.15 x
2018-12-31 CN¥4.97 CN¥12.15 x
2019-12-31 CN¥5.51 CN¥12.15 x
2020-12-31 CN¥5.86 CN¥12.15 x
2021-12-31 CN¥6.31 CN¥12.15 x
2022-12-31 CN¥6.63 CN¥12.15 x
2023-12-31 CN¥6.99 CN¥12.15 x
2024-12-31 CN¥6.97 CN¥12.15 x

Capital Efficiency Dashboard

This dashboard shows how efficiently KPC Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 12.34%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 7.71%
  • • Asset Turnover: 0.67x
  • • Equity Multiplier: 2.40x
  • Recent ROE (12.34%) is above the historical average (10.67%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1997 12.72% 4.05% 0.89x 3.51x CN¥2.36 Million
1998 27.01% 6.09% 0.97x 4.55x CN¥15.17 Million
1999 24.26% 5.26% 1.04x 4.42x CN¥14.05 Million
2000 7.60% 7.60% 0.64x 1.56x CN¥-12.31 Million
2001 7.39% 7.85% 0.64x 1.47x CN¥-13.56 Million
2002 8.40% 8.83% 0.66x 1.44x CN¥-8.50 Million
2003 11.73% 10.58% 0.70x 1.58x CN¥10.38 Million
2004 9.54% 9.97% 0.55x 1.75x CN¥-3.06 Million
2005 -8.60% -3.69% 0.98x 2.39x CN¥-96.38 Million
2006 0.51% 0.23% 1.02x 2.15x CN¥-49.78 Million
2007 5.06% 2.25% 1.08x 2.07x CN¥-28.38 Million
2008 5.30% 2.45% 1.13x 1.91x CN¥-28.54 Million
2009 8.76% 4.06% 1.15x 1.87x CN¥-8.26 Million
2010 11.64% 4.71% 1.28x 1.93x CN¥12.05 Million
2011 15.90% 5.38% 1.48x 1.99x CN¥48.31 Million
2012 19.36% 6.03% 1.40x 2.29x CN¥87.88 Million
2013 13.18% 6.46% 1.24x 1.64x CN¥55.82 Million
2014 15.01% 6.69% 1.43x 1.57x CN¥96.41 Million
2015 12.71% 8.56% 0.99x 1.49x CN¥89.67 Million
2016 11.45% 7.98% 0.94x 1.52x CN¥51.50 Million
2017 9.00% 5.64% 0.92x 1.73x CN¥-36.49 Million
2018 8.78% 4.72% 1.03x 1.80x CN¥-46.52 Million
2019 10.83% 5.59% 1.09x 1.77x CN¥34.69 Million
2020 10.26% 5.92% 0.95x 1.82x CN¥11.79 Million
2021 10.61% 6.15% 0.93x 1.86x CN¥29.33 Million
2022 7.69% 4.63% 0.88x 1.89x CN¥-115.12 Million
2023 10.21% 6.41% 0.88x 1.81x CN¥10.97 Million
2024 12.34% 7.71% 0.67x 2.40x CN¥122.72 Million

Industry Comparison

This section compares KPC Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
KPC Pharmaceuticals Inc (600422) CN¥6.86 Billion 12.72% 0.75x $801.78 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million